Agreement - August 30, 2017
Genmab and Seattle Genetics in co-development agreement
Genmab and Seattle Genetics announces that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development. Tisotumab vedotin, […]
Pharma Business - May 3, 2017
Genmab announces European marketing authorization for DARZALEX
Genmab announces that the European Commission (EC) has granted a marketing authorization for DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The EC approval follows a positive opinion issued for DARZALEX by the Committee […]
Clinical Trials - May 2, 2017
Genmab announces new phase III study
Genmab announces that Janssen Research & Development, LLC, in collaboration with the European Myeloma Network (EMN) and Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), plans to start a Phase III study of daratumumab in relapsed and refractory multiple myeloma. The study (MMY3013, APOLLO) is a randomized Phase III that will compare daratumumab in combination with pomalidomide […]
In a new job - February 9, 2017
Genmab appoints new Chief Development Officer
Genmab has appointed Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer (CDO). Dr. Klimovsky will lead the company’s global product development activities and will join the Executive team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell. Klimovsky will be responsible for Genmab’s product development strategy in […]
Pharma Business - January 9, 2017
Genmab receives USD 25 million in sales milestone
Genmab A/S has achieved the first sales volume milestone in its DARZALEX (daratumumab) collaboration with Janssen. The USD 25 million milestone was triggered by sales of DARZALEX reaching USD 500 million in a calendar year. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize DARZALEX. “We have […]
Pharma Business - November 22, 2016
FDA approval for Genmab
The U.S. Food and Drug Administration (FDA) has approved the use of Genmab’s DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. In July 2016, daratumumab was granted a Breakthrough Therapy Designation (BTD) in this patient […]
